BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).
暂无分享，去创建一个
J. Desai | K. Gelmon | F. D. De Braud | G. Curigliano | J. Tabernero | L. Siu | B. Markman | M. Carlino | V. Moreno | P. Basciano | J. Luke | S. Patel | A. Joshua | A. Varga | C. Gomez-Roca | M. Wind-Rotolo | Y. Ishii | Zhaohui Liu | Alex Azrilevich